Date: October 27, 2026

Financial Performance Summary

Quarterly Performance (Q2 FY27 vs Q2 FY26)

  • Revenue from operations: ₹572 crores (up 21.0% from ₹473 crores)
  • EBITDA: ₹64 crores (up 90.2% from ₹34 crores)
  • EBITDA margin: 11.2% (vs 7.1%)
  • Profit before tax: ₹65 crores (up 71.7% from ₹38 crores)
  • Profit after tax: ₹49 crores (up 72.9% from ₹28 crores)
  • EPS: ₹3.01 (up 72.2% from ₹1.75)

Half-Yearly Performance (H1 FY27 vs H1 FY26)

  • Revenue from operations: ₹1,240 crores (up 10.6% from ₹1,121 crores)
  • EBITDA: ₹210 crores (up 19.4% from ₹176 crores)
  • EBITDA margin: 16.9% (vs 15.7%)
  • Profit before tax: ₹240 crores (up 21.4% from ₹198 crores)
  • Profit after tax: ₹181 crores (up 21.3% from ₹150 crores)
  • EPS: ₹11.15 (up 21.2% from ₹9.20)

Segment-wise Performance

Domestic Formulations

  • Q2 FY27: ₹467 crores (up 22.6% YoY)
  • H1 FY27: ₹1,036 crores (up 7.8% YoY)
  • Accounted for approximately 84% of consolidated sales in H1
  • Growth driven by flagship brands Electral and Enerzal, with Zifi returning to growth
  • According to IQVIA secondary sales data: 21.4% growth for quarter, 8.2% growth for MAT ended September 30, 2026
  • FDC was fastest-growing company among top 25 corporates in Indian Pharmaceutical Market in Q2 FY27

International Formulations

  • Q2 FY27: ₹75 crores (up 28.5% YoY)
  • US market: ₹30 crores (up 109.7% YoY)
  • Non-US markets: ₹45 crores (up 1.6% YoY)
  • H1 FY27: ₹148 crores (up 47.6% YoY)
  • US market: ₹65 crores (up 99.7% YoY)
  • Non-US markets: ₹83 crores (up 22.8% YoY)
  • Accounted for approximately 12% of consolidated sales

API Business

  • Q2 FY27: ₹28 crores (down 4.8% YoY)
  • H1 FY27: ₹52 crores (down 4.0% YoY)
  • Accounted for approximately 4% of consolidated sales
  • Decline mainly due to lower sales of one key molecule

Business Context

FDC Limited is a pharmaceutical company established in 1936 and incorporated in 1940. The company has manufacturing facilities at Roha, Waluj, Sinnar (Maharashtra), Verna (Goa), and Baddi (Himachal Pradesh). It markets more than 300 products in India and exports to over 50 countries. The company holds accreditations from US-FDA, UK-MHRA, SAPHRA, and UAE.

Forward-Looking Statement Disclaimer

The press release contains forward-looking statements subject to risks and uncertainties including strategy implementation, growth plans, regulatory approvals, technological changes, earnings fluctuations, foreign exchange rates, international operations management, and market risks.